280Bio cleared to advance KRAS inhibitor YL-17231 into clinic in US
July 10, 2023
280Bio Inc. has received FDA approval of its IND application for the KRAS inhibitor YL-17231. 280Bio will start phase I enrollment in the U.S. in the fourth quarter of this year for the treatment of advanced cancer patients with RAS mutations in their tumors.